smithklin beckman corp said pursu three point stragey will achiev pct annual increas oper earn throughout remaind decad 1986 smithklin earn 521 mln dlrs dlrs per share revenu billion dlrs compani said it annual report it nonpharmaceut busi will play major role meet it earn growth target and will fact grow faster it pharmaceut busi smithklin whose major product antiulc medic tagamet said report intend improv earn from exist product expand it product portfolio and optim it financi resourc bolster it posit antiulc market which tagamet has met stiff competit smithklin said it strategi develop over counter version tagamet bolster two joint ventur with and pend ventur japan smithklin also said it allergan inc eye and skin care product divis can billion dlr organ next five year can grow more seven pct annual nondilut acquisit real possibl gavin herbert presid eye and skin care product group said report 1986 allergan had worldwid sale 433 mln dlrs said it smith kline and french laboratori pharmaceut unit with 1986 sale billion dlrs will file for food and drug administr market approv for number cardiovascular agent includ tissu plasminogen activ over next two year also said and sale forc will pct larger 1987 with more 000 sale personnel smith kline also said it small clinic laboratori test unit with 1986 sale 373 mln dlrs perform mln test year and see increas employe drug test well test for aid antibodi smith kline said depend it share price and cost money may buy back more share last three year has bought back about pct it share smithklin begin year with new manag team includ it new chief oper offic georg ebright reuter 